EVIO Obtains Mandatory Laboratory Accreditation in Massachusetts

Cannabis Investing News

EVIO announced its Massachusetts laboratory obtained the mandatory accreditation needed to operate as a testing laboratory.

EVIO (OTCQB:EVIO) announced its Massachusetts laboratory obtained the mandatory accreditation needed to operate as a testing laboratory.

As quoted in the press release:

EVIO a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, announced today that its Massachusetts laboratory has attained ISO/IEC 17025 accreditation from American Association for Laboratory Accreditation (A2LA). ISO 17025 accreditation is mandatory in Massachusetts for all independent testing laboratories.

ISO/IEC 17025 is the highest recognized quality standard in the world for calibration and testing laboratories. For an organization to be accredited in ISO/IEC 17025, its laboratory is assessed to determine they can consistently produce precise and accurate tests for cannabinoids, pesticides, and contaminants, and have implemented a rigorous quality management system. This also requires personnel to be deemed competent to perform all testing on the scope of accreditation.

“We are very proud of all of the teams’ hard work that resulted in this advanced accreditation,” said James Kocis, Lab Director of EVIO Labs Massachusetts. “With the state-mandated laboratory regulations, EVIO upholds the high standards of testing and plays a pivotal role in ensuring consumer safety and confidence in the states burgeoning marijuana market.”

Click here to read the full press release.

The Conversation (0)
×